Oxford Biomedica broadens relationship with Kadans with Harrow House sale and lease back deal

Oxford Biomedica, the biotech company, said it had broadened its relationship with Kadans Science Partner via a sale and lease back deal concerning the former's purpose built manufacturing facility Harrow House in Oxford.

Kadans will buy the asset then lease it back, in its entirety, to Oxford Biomedica, a contract development and manufacturing organisation (CDMO), which serves some of the world’s most innovative pharmaceutical and biotechnology companies.

READ MORE: Oxford biotech Exscientia adds two drugs to cancer pipeline

With this acquisition of Harrow House, the Kadans portfolio now consists of more than 65 buildings and numerous projects under development in the Netherlands, United Kingdom, Germany, Belgium, France and Spain.

European group Kadans aims to partner with universities, venture capital firms and others to create a knowledge-sharing ecosystem of scientific enterprise across Europe.

It is currently present on 28 campuses, in six countries and has over 450 tenants, including start-ups, corporates, and government bodies.

Nick Page, chief operations officer at Oxford Biomedica said: "We welcome this opportunity to broaden our ongoing relationship with Kadans.

"This transaction enables us to maximise value from our earlier investment and assists with future growth opportunities as we build our position as a quality and innovation-led viral vector CDMO."

James Sheppard, managing director (UK & Ireland) at Kadans, added: "We are pleased to be continuing to build our relationship with Oxford Biomedica.

"Harrow House has long played an important role for Oxford Biomedica and we look forward to working with them on the next stage of its evolution."

Kadans was supported in the transaction by Knight Frank and Mills & Reeve acted as legal advisors for Kadans. Plainlaw acted as legal advisors to Oxford Biomedica.

Visit Hampshire Biz News for bright, upbeat and positive business news from the county